{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T05:12:41Z","timestamp":1776834761939,"version":"3.51.2"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01AI113267"],"award-info":[{"award-number":["R01AI113267"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hepatitis B Foundation"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.antiviral.2015.07.006","type":"journal-article","created":{"date-parts":[[2015,7,20]],"date-time":"2015-07-20T13:20:17Z","timestamp":1437398417000},"page":"152-159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Treatment of chronic hepatitis B with pattern recognition receptor agonists: Current status and potential for a cure"],"prefix":"10.1016","volume":"121","author":[{"given":"Jinhong","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju-Tao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.antiviral.2015.07.006_b0005","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.cell.2006.02.015","article-title":"Pathogen recognition and innate immunity","volume":"124","author":"Akira","year":"2006","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.antiviral.2015.07.006_b0010","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jhep.2013.10.021","article-title":"Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-alpha administration","volume":"60","author":"Allweiss","year":"2013","journal-title":"J. Hepatol."},{"issue":"8359","key":"10.1016\/j.antiviral.2015.07.006_b0015","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S0140-6736(83)90624-4","article-title":"Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine","volume":"2","author":"Beasley","year":"1983","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.antiviral.2015.07.006_b0020","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1172\/JCI58847","article-title":"IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome","volume":"122","author":"Belloni","year":"2012","journal-title":"J. Clin. Invest."},{"issue":"12","key":"10.1016\/j.antiviral.2015.07.006_b0025","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1136\/gutjnl-2011-301073","article-title":"Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection","volume":"61","author":"Bertoletti","year":"2011","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.antiviral.2015.07.006_b0030","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1586\/egh.09.48","article-title":"Therapeutic vaccination and novel strategies to treat chronic HBV infection","volume":"3","author":"Bertoletti","year":"2009","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"issue":"12","key":"10.1016\/j.antiviral.2015.07.006_b0035","doi-asserted-by":"crossref","first-page":"e1003784","DOI":"10.1371\/journal.ppat.1003784","article-title":"Immune therapeutic strategies in chronic hepatitis B virus infection: virus or inflammation control?","volume":"9","author":"Bertoletti","year":"2013","journal-title":"PLoS Pathog."},{"issue":"1","key":"10.1016\/j.antiviral.2015.07.006_b0040","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/ni.2491","article-title":"STING and the innate immune response to nucleic acids in the cytosol","volume":"14","author":"Burdette","year":"2013","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.antiviral.2015.07.006_b0045","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.antiviral.2012.10.001","article-title":"The innate immune response to hepatitis B virus infection: implications for pathogenesis and therapy","volume":"96","author":"Chang","year":"2012","journal-title":"Antiviral Res."},{"issue":"4","key":"10.1016\/j.antiviral.2015.07.006_b0050","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.apsb.2014.05.002","article-title":"Therapeutic strategies for a functional cure of chronic hepatitis B virus infection","volume":"4","author":"Chang","year":"2014","journal-title":"Acta Pharm. Sin. B"},{"issue":"7","key":"10.1016\/j.antiviral.2015.07.006_b0055","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1073\/pnas.1424775112","article-title":"Age-related immune clearance of hepatitis B virus infection requires the establishment of gut microbiota","volume":"112","author":"Chou","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"4","key":"10.1016\/j.antiviral.2015.07.006_b0060","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/2051013613501988","article-title":"Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants","volume":"1","author":"Dubensky","year":"2013","journal-title":"Ther. Adv. Vaccines"},{"issue":"4","key":"10.1016\/j.antiviral.2015.07.006_b0065","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1053\/j.gastro.2009.06.054","article-title":"Temporal analysis of early immune responses in patients with acute hepatitis B virus infection","volume":"137","author":"Dunn","year":"2009","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.antiviral.2015.07.006_b0070","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/gut.2008.163600","article-title":"Early kinetics of innate and adaptive immune responses during hepatitis B virus infection","volume":"58","author":"Fisicaro","year":"2009","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.antiviral.2015.07.006_b0075","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/hep.25730","article-title":"Transcriptomic analysis of the woodchuck model of chronic hepatitis B","volume":"56","author":"Fletcher","year":"2012","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.antiviral.2015.07.006_b0080","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1124\/jpet.113.207878","article-title":"Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel Toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses","volume":"348","author":"Fosdick","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"283","key":"10.1016\/j.antiviral.2015.07.006_b0085","doi-asserted-by":"crossref","first-page":"283ra52","DOI":"10.1126\/scitranslmed.aaa4306","article-title":"STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade","volume":"7","author":"Fu","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.antiviral.2015.07.006_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2015.02.037","article-title":"The oral Toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection","author":"Gane","year":"2015","journal-title":"J. Hepatol."},{"issue":"6148","key":"10.1016\/j.antiviral.2015.07.006_b0095","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1126\/science.1240933","article-title":"Cyclic GMP-AMP synthase is an innate immune sensor of HIV and other retroviruses","volume":"341","author":"Gao","year":"2013","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.antiviral.2015.07.006_b0100","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/mt.2013.274","article-title":"Immunological and antiviral responses after therapeutic DNA immunization in chronic hepatitis B patients efficiently treated by analogues","volume":"22","author":"Godon","year":"2013","journal-title":"Mol. Ther."},{"issue":"1\u20132","key":"10.1016\/j.antiviral.2015.07.006_b0105","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cellimm.2012.07.006","article-title":"Evidence for cyclic diguanylate as a vaccine adjuvant with novel immunostimulatory activities","volume":"278","author":"Gray","year":"2012","journal-title":"Cell. Immunol."},{"issue":"1","key":"10.1016\/j.antiviral.2015.07.006_b0110","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1074-7613(00)80295-2","article-title":"Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes","volume":"4","author":"Guidotti","year":"1996","journal-title":"Immunity"},{"issue":"5415","key":"10.1016\/j.antiviral.2015.07.006_b0115","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1126\/science.284.5415.825","article-title":"Viral clearance without destruction of infected cells during acute HBV infection","volume":"284","author":"Guidotti","year":"1999","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.antiviral.2015.07.006_b0120","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1128\/AAC.04321-14","article-title":"STING agonists induce an innate antiviral immune response against hepatitis B virus","volume":"59","author":"Guo","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.07.006_b0125","doi-asserted-by":"crossref","DOI":"10.1172\/JCI79915","article-title":"Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants","author":"Hanson","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"46","key":"10.1016\/j.antiviral.2015.07.006_b0130","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1016\/j.vaccine.2013.05.068","article-title":"Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40\u201370years of age","volume":"31","author":"Heyward","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2015.07.006_b0135","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1038\/ncomms7588","article-title":"Trained immunity in newborn infants of HBV-infected mothers","volume":"6","author":"Hong","year":"2015","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.antiviral.2015.07.006_b0140","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2012.03.006","article-title":"Transfer of HBV genomes using low doses of adenovirus vectors leads to persistent infection in immune competent mice","volume":"142","author":"Huang","year":"2012","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.antiviral.2015.07.006_b0145","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/ni.2573","article-title":"Intrahepatic myeloid-cell aggregates enable local proliferation of CD8(+) T cells and successful immunotherapy against chronic viral liver infection","volume":"14","author":"Huang","year":"2013","journal-title":"Nat. Immunol."},{"issue":"7213","key":"10.1016\/j.antiviral.2015.07.006_b0150","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nature07317","article-title":"STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling","volume":"455","author":"Ishikawa","year":"2008","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.antiviral.2015.07.006_b0155","doi-asserted-by":"crossref","first-page":"7269","DOI":"10.1128\/JVI.79.11.7269-7272.2005","article-title":"Toll-like receptor signaling inhibits hepatitis B virus replication in vivo","volume":"79","author":"Isogawa","year":"2005","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.antiviral.2015.07.006_b0160","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/ni.3123","article-title":"Control of adaptive immunity by the innate immune system","volume":"16","author":"Iwasaki","year":"2015","journal-title":"Nat. Immunol."},{"issue":"46","key":"10.1016\/j.antiviral.2015.07.006_b0165","doi-asserted-by":"crossref","first-page":"5306","DOI":"10.1016\/j.vaccine.2013.05.067","article-title":"Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease","volume":"31","author":"Janssen","year":"2013","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.antiviral.2015.07.006_b0170","doi-asserted-by":"crossref","first-page":"e1004210","DOI":"10.1371\/journal.ppat.1004210","article-title":"Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver","volume":"10","author":"Jo","year":"2014","journal-title":"PLoS Pathog."},{"issue":"5","key":"10.1016\/j.antiviral.2015.07.006_b0175","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nm1589","article-title":"Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists","volume":"13","author":"Kanzler","year":"2007","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.antiviral.2015.07.006_b0180","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1053\/j.gastro.2013.12.036","article-title":"Hepatic immune regulation and its involvement in viral hepatitis infection","volume":"146","author":"Knolle","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2015.07.006_b0185","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1471-2334-10-103","article-title":"Cellular immunity in children with successful immunoprophylactic treatment for mother-to-child transmission of hepatitis B virus","volume":"10","author":"Komatsu","year":"2010","journal-title":"BMC Infect. Dis."},{"issue":"6","key":"10.1016\/j.antiviral.2015.07.006_b0190","doi-asserted-by":"crossref","first-page":"e1003391","DOI":"10.1371\/journal.ppat.1003391","article-title":"Combination of DNA prime\u2013adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model","volume":"9","author":"Kosinska","year":"2013","journal-title":"PLoS Pathog."},{"issue":"6","key":"10.1016\/j.antiviral.2015.07.006_b0195","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/cmi.2010.34","article-title":"Hepatitis B-specific T helper cell responses in uninfected infants born to HBsAg+\/HBeAg\u2212 mothers","volume":"7","author":"Koumbi","year":"2010","journal-title":"Cell. Mol. Immunol."},{"issue":"7","key":"10.1016\/j.antiviral.2015.07.006_b0200","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1053\/j.gastro.2013.02.003","article-title":"GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees","volume":"144","author":"Lanford","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2015.07.006_b0205","doi-asserted-by":"crossref","DOI":"10.3851\/IMP2845","article-title":"Safety, pharmacokinetics and pharmacodynamics of the oral Toll-like receptor 7 agonist GS-9620 in treatment-naive patients with chronic hepatitis C","author":"Lawitz","year":"2014","journal-title":"Antivir. Ther."},{"issue":"24","key":"10.1016\/j.antiviral.2015.07.006_b0210","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1056\/NEJM199712113372406","article-title":"Hepatitis B virus infection","volume":"337","author":"Lee","year":"1997","journal-title":"N. Engl. J. Med."},{"issue":"5 Suppl.","key":"10.1016\/j.antiviral.2015.07.006_b0215","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1002\/hep.22881","article-title":"Hepatitis B: the virus and disease","volume":"49","author":"Liang","year":"2009","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.antiviral.2015.07.006_b0220","doi-asserted-by":"crossref","first-page":"e1004780","DOI":"10.1371\/journal.ppat.1004780","article-title":"TGF-beta suppression of HBV RNA through AID-dependent recruitment of an RNA exosome complex","volume":"11","author":"Liang","year":"2015","journal-title":"PLoS Pathog."},{"issue":"Suppl. 1","key":"10.1016\/j.antiviral.2015.07.006_b0225","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/liv.12057","article-title":"Impact of therapy on the outcome of chronic hepatitis B","volume":"33","author":"Liaw","year":"2013","journal-title":"Liver Int."},{"issue":"9","key":"10.1016\/j.antiviral.2015.07.006_b0230","doi-asserted-by":"crossref","first-page":"e1003613","DOI":"10.1371\/journal.ppat.1003613","article-title":"Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes","volume":"9","author":"Liu","year":"2013","journal-title":"PLoS Pathog."},{"issue":"1","key":"10.1016\/j.antiviral.2015.07.006_b0235","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12250-014-3410-5","article-title":"New therapeutic vaccination strategies for the treatment of chronic hepatitis B","volume":"29","author":"Liu","year":"2014","journal-title":"Virol. Sin."},{"issue":"1","key":"10.1016\/j.antiviral.2015.07.006_b0240","doi-asserted-by":"crossref","first-page":"e1003856","DOI":"10.1371\/journal.ppat.1003856","article-title":"Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection","volume":"10","author":"Liu","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2015.07.006_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2015.06.022","article-title":"Expression and functionality of Toll- and RIG-like receptors in HepaRG cells","author":"Luangsay","year":"2015","journal-title":"J. Hepatol."},{"issue":"6176","key":"10.1016\/j.antiviral.2015.07.006_b0250","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.antiviral.2015.07.006_b0255","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1053\/j.gastro.2011.02.057","article-title":"Hepatitis B virus limits response of human hepatocytes to interferon-alpha in chimeric mice","volume":"140","author":"Lutgehetmann","year":"2011","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.antiviral.2015.07.006_b0260","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1503\/cmaj.081112","article-title":"Hepatitis B immunization strategies: timing is everything","volume":"180","author":"Mackie","year":"2009","journal-title":"CMAJ"},{"issue":"11","key":"10.1016\/j.antiviral.2015.07.006_b0265","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1172\/JCI200317470","article-title":"Mature CD8(+) T lymphocyte response to viral infection during fetal life","volume":"111","author":"Marchant","year":"2003","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.antiviral.2015.07.006_b0270","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3748\/wjg.v13.i1.104","article-title":"The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection","volume":"13","author":"Menne","year":"2007","journal-title":"World J. Gastroenterol."},{"issue":"6","key":"10.1016\/j.antiviral.2015.07.006_b0275","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jhep.2014.12.026","article-title":"Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B","volume":"62","author":"Menne","year":"2015","journal-title":"J. Hepatol."},{"issue":"12","key":"10.1016\/j.antiviral.2015.07.006_b0280","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","article-title":"Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity","volume":"30","author":"Ott","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2015.07.006_b0285","doi-asserted-by":"crossref","DOI":"10.1038\/nm.3856","article-title":"Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells","author":"Pallett","year":"2015","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.antiviral.2015.07.006_b0290","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.immuni.2013.05.004","article-title":"Immune sensing of DNA","volume":"38","author":"Paludan","year":"2013","journal-title":"Immunity"},{"issue":"5 Suppl.","key":"10.1016\/j.antiviral.2015.07.006_b0295","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1002\/hep.22956","article-title":"Benefits and risks of interferon therapy for hepatitis B","volume":"49","author":"Perrillo","year":"2009","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.antiviral.2015.07.006_b0300","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1172\/JCI44198","article-title":"IL-21 is pivotal in determining age-dependent effectiveness of immune responses in a mouse model of human hepatitis B","volume":"121","author":"Publicover","year":"2011","journal-title":"J. Clin. Invest."},{"issue":"9","key":"10.1016\/j.antiviral.2015.07.006_b0305","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1172\/JCI68182","article-title":"Age-dependent hepatic lymphoid organization directs successful immunity to hepatitis B","volume":"123","author":"Publicover","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.antiviral.2015.07.006_b0310","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.immuni.2014.12.016","article-title":"The RNA sensor RIG-I dually functions as an innate sensor and direct antiviral factor for hepatitis B virus","volume":"42","author":"Sato","year":"2015","journal-title":"Immunity"},{"issue":"33","key":"10.1016\/j.antiviral.2015.07.006_b0315","doi-asserted-by":"crossref","first-page":"12193","DOI":"10.1073\/pnas.1412631111","article-title":"Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems","volume":"111","author":"Shlomai","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"20","key":"10.1016\/j.antiviral.2015.07.006_b0320","doi-asserted-by":"crossref","first-page":"11652","DOI":"10.1073\/pnas.1635109100","article-title":"Hepatocyte turnover during resolution of a transient hepadnaviral infection","volume":"100","author":"Summers","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"6","key":"10.1016\/j.antiviral.2015.07.006_b0325","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.cell.2010.01.022","article-title":"Pattern recognition receptors and inflammation","volume":"140","author":"Takeuchi","year":"2010","journal-title":"Cell"},{"issue":"Pt 2","key":"10.1016\/j.antiviral.2015.07.006_b0330","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1099\/vir.0.015529-0","article-title":"The early host innate immune response to duck hepatitis B virus infection","volume":"91","author":"Tohidi-Esfahani","year":"2010","journal-title":"J. Gen. Virol."},{"issue":"4","key":"10.1016\/j.antiviral.2015.07.006_b0335","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1084\/jem.20090348","article-title":"Human cytomegalovirus elicits fetal gammadelta T cell responses in utero","volume":"207","author":"Vermijlen","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.antiviral.2015.07.006_b0340","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ijid.2014.07.015","article-title":"Immunizations with hepatitis B viral antigens and a TLR7\/8 agonist adjuvant induce antigen-specific immune responses in HBV-transgenic mice","volume":"29","author":"Wang","year":"2014","journal-title":"Int. J. Infect. Dis."},{"issue":"44","key":"10.1016\/j.antiviral.2015.07.006_b0345","doi-asserted-by":"crossref","first-page":"31715","DOI":"10.1074\/jbc.M113.501122","article-title":"Interleukin-1 and tumor necrosis factor-alpha trigger restriction of hepatitis B virus infection via a cytidine deaminase activation-induced cytidine deaminase (AID)","volume":"288","author":"Watashi","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.antiviral.2015.07.006_b0350","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.coi.2009.12.005","article-title":"TLR signalling regulated antigen presentation in dendritic cells","volume":"22","author":"Watts","year":"2010","journal-title":"Curr. Opin. Immunol."},{"issue":"15","key":"10.1016\/j.antiviral.2015.07.006_b0355","doi-asserted-by":"crossref","first-page":"9369","DOI":"10.1128\/JVI.79.15.9369-9380.2005","article-title":"Stealth and cunning: hepatitis B and hepatitis C viruses","volume":"79","author":"Wieland","year":"2005","journal-title":"J. Virol."},{"issue":"17","key":"10.1016\/j.antiviral.2015.07.006_b0360","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1073\/pnas.0401771101","article-title":"Genomic analysis of the host response to hepatitis B virus infection","volume":"101","author":"Wieland","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"28","key":"10.1016\/j.antiviral.2015.07.006_b0365","doi-asserted-by":"crossref","first-page":"9913","DOI":"10.1073\/pnas.0504273102","article-title":"Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids","volume":"102","author":"Wieland","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"6","key":"10.1016\/j.antiviral.2015.07.006_b0370","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/hep.21897","article-title":"Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice","volume":"46","author":"Wu","year":"2007","journal-title":"Hepatology"},{"issue":"18","key":"10.1016\/j.antiviral.2015.07.006_b0375","doi-asserted-by":"crossref","first-page":"10421","DOI":"10.1128\/JVI.00996-14","article-title":"Poly(I:C) treatment leads to interferon-dependent clearance of hepatitis B virus in a hydrodynamic injection mouse model","volume":"88","author":"Wu","year":"2014","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.antiviral.2015.07.006_b0380","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/hep.21282","article-title":"Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B","volume":"44","author":"Wursthorn","year":"2006","journal-title":"Hepatology"},{"issue":"18","key":"10.1016\/j.antiviral.2015.07.006_b0385","doi-asserted-by":"crossref","first-page":"9332","DOI":"10.1128\/JVI.00918-10","article-title":"Interferons accelerate decay of replication-competent nucleocapsids of hepatitis B virus","volume":"84","author":"Xu","year":"2010","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.antiviral.2015.07.006_b0390","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jhep.2013.05.003","article-title":"Results of a phase III clinical trial with an HBsAg\u2013HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings","volume":"59","author":"Xu","year":"2013","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.antiviral.2015.07.006_b0395","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/cmi.2013.43","article-title":"A mouse model for HBV immunotolerance and immunotherapy","volume":"11","author":"Yang","year":"2014","journal-title":"Cell. Mol. Immunol."},{"issue":"7","key":"10.1016\/j.antiviral.2015.07.006_b0400","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1038\/nm.2811","article-title":"Hepatitis B virus-induced lipid alterations contribute to natural killer T cell-dependent protective immunity","volume":"18","author":"Zeissig","year":"2012","journal-title":"Nat. Med."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354215001692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354215001692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T16:23:43Z","timestamp":1537460623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354215001692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":80,"alternative-id":["S0166354215001692"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2015.07.006","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of chronic hepatitis B with pattern recognition receptor agonists: Current status and potential for a cure","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2015.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}